Leukemia

The Leukemia & Lymphoma has collaborated with cancer institutions, foundations and philanthropic individuals to fund several cancer research projects.

Approximately 29% of older patients with chronic myeloid leukemia did not initiate tyrosine kinase inhibitor therapy within 6 months of diagnosis, according to study results published in Journal of Clinical Oncology.

Maintenance therapy with oral azacitidine led to statistically significant and clinically meaningful improvements in OS and RFS among patients with acute myeloid leukemia in remission after induction chemotherapy.

Ninety percent of patients with relapsed B-cell acute lymphoblastic leukemia after allogeneic stem cell transplantation had complete response to an investigational chimeric antigen receptor T-cell therapy, according to preliminary data.

An investigational chimeric antigen receptor T-cell therapy showed antitumor activity among patients with relapsed or refractory B-cell acute lymphoblastic leukemia, according to data presented at the virtual ASH Annual Meeting and Exposition.

The combination of umbralisib and ublituximab significantly improved PFS compared with chemoimmunotherapy for patients with chronic lymphocytic leukemia, according to study results presented at the virtual ASH Annual Meeting and Exposition.

Young patients with B-cell acute lymphoblastic leukemia had shorter RFS and EFS if they received blinatumomab before chimeric antigen receptor T-cell therapy, according to results presented at the virtual ASH Annual Meeting and Exposition.

The addition of venetoclax to azacitidine benefited untreated patients with isocitrate dehydrogenase mutations ineligible for intensive chemotherapy, according to study results presented at the virtual ASH Annual Meeting and Exposition.

Asciminib appeared to be more effective than bosutinib for certain patients with chronic-phase chronic myeloid leukemia who had been treated with at least two tyrosine kinase inhibitors, according to results of the phase 3 ASCEMBL study.

Patients with chronic lymphocytic leukemia who carried the IGLV3-21R110 mutation appeared to have poor outcomes, according to study results presented at the virtual ASH Annual Meeting and Exposition.